Portage Biotech Inc. (NASDAQ:PRTG – Get Rating) – Equities researchers at Oppenheimer lifted their Q2 2023 earnings per share (EPS) estimates for shares of Portage Biotech in a research report issued to clients and investors on Wednesday, September 14th. Oppenheimer analyst M. Biegler now expects that the company will earn ($0.26) per share for the quarter, up from their prior forecast of ($0.28). Oppenheimer has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Portage Biotech’s current full-year earnings is ($0.95) per share. Oppenheimer also issued estimates for Portage Biotech’s Q3 2023 earnings at ($0.27) EPS, Q4 2023 earnings at ($0.28) EPS, FY2023 earnings at ($0.96) EPS and FY2024 earnings at ($1.27) EPS.
Portage Biotech (NASDAQ:PRTG – Get Rating) last posted its earnings results on Monday, August 1st. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.28).
Portage Biotech Price Performance
Hedge Funds Weigh In On Portage Biotech
Several institutional investors and hedge funds have recently bought and sold shares of PRTG. Citadel Advisors LLC purchased a new stake in shares of Portage Biotech in the second quarter worth about $137,000. Millennium Management LLC bought a new position in shares of Portage Biotech during the second quarter valued at approximately $92,000. Beacon Investment Advisory Services Inc. bought a new position in shares of Portage Biotech during the second quarter valued at approximately $80,000. Sigma Planning Corp purchased a new stake in shares of Portage Biotech in the first quarter valued at approximately $75,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Portage Biotech in the second quarter valued at approximately $79,000. 0.97% of the stock is currently owned by hedge funds and other institutional investors.
About Portage Biotech
Portage Biotech Inc, together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury.
- Get a free copy of the StockNews.com research report on Portage Biotech (PRTG)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.